Table 3 Subgroup analysis with patients showing a decrease in postprandial blood glucose (n = 32)
From: Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
| Â | Placebo | Saxagliptin | p-value |
|---|---|---|---|
Clinical characteristics | Â | Â | Â |
  HbA1c (%) | 7.19 ± 0.2 | 6.89 ± 0.2 | < 0.001 |
  Glucose postprandial (mmol/L) | 10.4 ± 0.4 | 9.05 ± 0.4 | < 0.001 |
  Glucose fasting (mmol/L) | 7.60 ± 0.4 | 7.21 ± 0.3 | 0.077 |
  Office SBP (mmHg) | 132 ± 2.8 | 131 ± 2.6 | 0.564 |
  Office DBP (mmHg) | 80 ± 1.4 | 79 ± 1.4 | 0.577 |
  Weight (kg) | 90.6 ± 2.4 | 91.0 ± 2.5 | 0.162 |
  Total cholesterol (mmol/L) | 5.34 ± 0.1 | 5.08 ± 0.1 | 0.011 |
  LDL cholesterol (mmol/L) | 3.73 ± 0.1 | 3.50 ± 0.1 | 0.013 |
  HDL cholesterol (mmol/L) | 1.19 ± 0.03 | 1.14 ± 0.03 | < 0.001 |
  Triglycerides (mmol/L) | 1.85 ± 0.2 | 1.83 ± 0.2 | 0.802 |
Retinal capillary flow | |||
  RCF basal (AU) | 314 ± 16.6 | 280 ± 12.1 | 0.011 |
  RCF flicker (AU) | 334 ± 16.3 | 319 ± 18.7 | 0.243 |
  ∆ (AU) | 19.1 ± 10.1 | 35.6 ± 10.9 | 0.306 |
  ∆ (%) | 7.3 ± 2.7 | 12.1 ± 3.1 | 0.299 |
  RCF pre L-NMMA (AU) | 319 ± 12.4 | 296 ± 12.3 | 0.041 |
  RCF post L-NMMA (AU) | 309 ± 12.6 | 297 ± 14.2 | 0.371 |
  ∆ (AU) | - 9.8 ± 6.5 | 1.1 ± 8.2 | 0.344 |
  ∆ (%) | - 2.8 ± 2.1 | 0.7 ± 2.6 | 0.339 |
Retinal arteriolar structure | |||
  WLR (-) | 0.38 ± 0.01 | 0.38 ± 0.02 | 0.837 |
  WT (μm) | 14.8 ± 0.6 | 14.5 ± 0.7 | 0.564 |
  Vessel diameter (μm) | 108 ± 2.1 | 106 ± 2.5 | 0.261 |
  Lumen diameter (μm) | 78 ± 1.5 | 77.4 ± 1.8 | 0.362 |
Macrocirculation | Â | Â | Â |
  Central SBP (mmHg) | 123 ± 2.5 | 119 ± 2.0 | 0.080 |
  Central PP (mmHg) | 46.0 ± 2.3 | 41.9 ± 2.4 | 0.051 |
  Central AP (mmHg) | 13.3 ± 1.1 | 11.7 ± 1.1 | 0.122 |
  cAlx@75 (%) | 24.7 ± 1.3 | 23.6 ± 1.4 | 0.367 |
  PWV (m/s) | 8.39 ± 0.24 | 8.38 ± 0.27 | 0.971 |
  UACR (mg/ g creatinine) | 5.0 (4.0 – 11.0) | 6.0 (3.25 – 9.0) | 0.740 |